A Phase 3 interventional study of Berobenatide and Placebo in Apnea, Sleep Disorders and Overweight and/or Obesity, sponsored by Pfizer. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive sleep apnea [OSA]) and overweight or obesity who are not using a breathing machine (positive airway pressure [PAP] machine).
People may be able to take part if they are adults with moderate to severe OSA, have overweight or obesity, and have been unable or unwilling using PAP therapy before joining the study. Participants will be assigned by chance to receive either berobenatide or a placebo (a treatment that looks like the study medicine but contains no active medicine). The study treatment will be given as an injection under the skin approximately once a month. Participants will receive study treatment at study sites and may administer some doses at home after receiving training.
During the study, participants will attend study visits, undergo sleep studies, complete questionnaires, and have health assessments performed. Researchers will compare the effects of berobenatide and placebo on sleep apnea, body weight, and other health measures.
1,417 studies on the registry are indexed under Apnea; 152 are open to participants now.
This study's planned enrollment of 258 is above the median of 51 across 962 interventional studies indexed under Apnea.
Browse Apnea studies →Pfizer is the lead sponsor of 3,323 studies on the registry; 145 are open to participants now.
Of its 597 completed or terminated interventional studies of FDA-regulated products, 391 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants receive berobenatide by subcutaneous injection.
Drug: Berobenatide
Participants receive volume-matched placebo
Drug: Placebo
Subcutaneous injection
Also known as: PF-08653944, MET097
Volume-matched subcutaneous placebo.
Change From Baseline in Apnea-Hypopnea Index
Apnea-Hypopnea Index is the number of apnea and hypopnea events per hour of sleep, assessed by polysomnography.
Time frame: Baseline, Week 52
Percent Change From Baseline in Body Weight
Time frame: Baseline, Week 52
Change From Baseline in High-Sensitivity C-Reactive Protein
Time frame: Baseline, Week 52
Percent Change From Baseline in Apnea-Hypopnea Index
Time frame: Baseline, Week 52
Percentage of Participants With at Least 50% Reduction in Apnea-Hypopnea Index
Time frame: Week 52
Change From Baseline in Sleep-Apnea-Specific Hypoxic Burden (SASHB)
Time frame: Baseline, Week 52
Percentage of Participants With Obstructive Sleep Apnea Remission or Mild Non-Symptomatic Obstructive Sleep Apnea
Time frame: Week 52
Change From Baseline in Systolic Blood Pressure
Time frame: Baseline, Week 52
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment 8a T-Score
Time frame: Baseline, Week 52
Change From Baseline in PROMIS Sleep Disturbance 8b T-Score
Time frame: Baseline, Week 52
Percentage of Participants with AHI <5
Time frame: Week 52
Percentage of Participants with AHI 5-14 with ESS (Epworth Sleepiness Scale) ≤10
Time frame: Week 52
Percentage of participants with AHI less then 15
Time frame: Week 52
Change From Baseline in Epworth Sleepiness Scale Total Score
Time frame: Baseline, Week 52
Change From Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials (IWQOL-Lite-CT) Physical Function Composite Score
Time frame: Baseline, Week 52
Change From Baseline in IWQOL-Lite-CT Physical Composite Score
Time frame: Baseline, Week 52
Change From Baseline in IWQOL-Lite-CT Psychosocial Composite Score
Time frame: Baseline, Week 52
Change From Baseline in IWQOL-Lite-CT Total Score
Score ranges from 0 to 100; higher scores indicate better quality of life.
Time frame: Baseline, Week 52
Change From Baseline in Body Weight
Time frame: Baseline, Week 52
Change From Baseline in Body Mass Index
Time frame: Baseline, Week 52
Change From Baseline in Waist Circumference
Time frame: Baseline, Week 52
Change From Baseline in Neck Circumference
Time frame: Baseline, Week 52
Change From Baseline in Short Form 36-Item (SF-36)
Time frame: Baseline, Week 52
Percentage of Participants With Improvement in Patient Global Impression of Severity (PGI-S) Sleepiness Category
Time frame: Week 52
Percentage of Participants With Improvement in Patient Global Impression of Severity (PGI-S) Fatigue Category
Time frame: Week 52
Percentage of Participants With Improvement in Patient Global Impression of Severity (PGI-S) Snoring Category
Time frame: Week 52
Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) Sleepiness
Time frame: Week 52
Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) Fatigue
Time frame: Week 52
Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) Sleep Quality
Time frame: Week 52
Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) Snoring
Time frame: Week 52
Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Index Score
Time frame: Baseline, Week 52
Change From Baseline in EuroQol-visual analog scale (EQ-VAS) Score
Time frame: Baseline, Week 52
Change From Baseline in WPAI:GH Presenteeism Score
Time frame: Baseline, Week 52
Change From Baseline in WPAI:GH Work Productivity Loss Score
Time frame: Baseline, Week 52
Change From Baseline in WPAI:GH Activity Impairment Score
Time frame: Baseline, Week 52
Number of participants with Treatment-Emergent Adverse Event (TEAE)
Time frame: Week 52
Number of participants with Serious Adverse Event (SAE)
Time frame: Week 52
Number of participants with Adverse event (AE) leading to permanent discontinuation from study intervention or study
Time frame: Week 52
Number of participants with Adverse Events of Special Interest (AESI)
Time frame: Week 52
Number of participants with clinical laboratory abnormalities
Time frame: Week 52
Change From Baseline in Diastolic Blood Pressure
Time frame: Baseline, Week 52
Change From Baseline in Total Cholesterol
Time frame: Baseline, Week 52
Change From Baseline in High-density lipoprotein cholesterol (HDL-C)
Time frame: Baseline, Week 52
Change From Baseline in Low-density lipoprotein cholesterol (LDL-C)
Time frame: Baseline, week 52
Change From Baseline in Non-HDL Cholesterol
Time frame: Baseline, Week 52
Change From Baseline in Very low-density lipoprotein cholesterol (VLDL) Cholesterol
Time frame: Baseline, Week 52
Change From Baseline in Triglycerides
Time frame: Baseline, Week 52
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Berobenatide